Sensei Biotherapeutics Shares Triple on Faeth Deal, $200M Raise

The stock climbed 177% to reach $25.32, extending its gains over the past year to approximately 169%. The $200 million funding round drew support from a heavy-hitting group of institutional investors, including Balyasny Asset Management, RA Capital Management, and Vivo Capital. This capital infusion provides the necessary runway to integrate Faeth’s technology, which focuses on drugs that target tumor metabolism and signaling.

A High-Stakes Strategic Pivot

The acquisition follows a volatile month for the company. On Oct. 17, Sensei initially reported positive dose expansion data for its drug solnerstotug, claiming the results supported a transition to Phase 2 trials. However, the company reversed course on Oct. 30, announcing it would discontinue the program, reduce its workforce, and seek a new direction—a path that has now culminated in the Faeth deal.

The private placement includes a broad coalition of healthcare-focused investors:

• B Group Capital and Columbia Threadneedle Investments
• Cormorant Asset Management and Fairmount
• Logos Capital, RA Capital Management, and Vivo Capital